IOL Chemicals & Pharmaceuticals Limited has submitted its quarterly compliance certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026. The filing, dated April 4, 2026, was communicated to both the National Stock Exchange of India Limited and BSE Limited through the company's registrar and share transfer agent.

Regulatory Compliance Filing

The certificate was issued by Alankit Assignments Limited, serving as the company's Registrar and Share Transfer Agent. The document confirms compliance with the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, specifically under Regulation 74(5) requirements.

Certificate Confirmation

Alankit Assignments Limited certified several key compliance points regarding the dematerialization process:

• Securities comprised in the certificates have been listed on stock exchanges
• Physical certificates received for dematerialization have been properly verified, mutilated, and cancelled
• The depository name has been substituted in records as the registered owner
• Required certificates were submitted to depositories and stock exchanges within specified time limits

Stock Exchange Communication

The compliance certificate was formally communicated to both major Indian stock exchanges where IOL Chemicals and Pharmaceuticals shares are traded. The company trades on NSE under the symbol IOLCP and on BSE under security code 524164.

Corporate Governance

The filing was signed by Abhay Raj Singh, Senior Vice President and Company Secretary of IOL Chemicals and Pharmaceuticals Limited. On behalf of the registrar, Kamal Garg, General Manager at Alankit Assignments Limited, digitally signed the compliance certificate.

This quarterly filing represents standard regulatory compliance for listed companies, ensuring proper documentation and transparency in the dematerialization process of physical share certificates during the quarter ended March 31, 2026.

IOL Chemicals & Pharmaceuticals Limited has announced the successful striking off of its wholly owned subsidiary, IOL Life Sciences Limited, from the Register of Companies. The Registrar of Companies, Ministry of Corporate Affairs, approved the application vide Notice No.STK-7/001115/2026 dated 1st April 2026.

Regulatory Compliance and Timeline

The company filed the application for striking off the subsidiary's name on 27th January 2026 under Section 248 of the Companies Act, 2013. This disclosure was made pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 13th July 2023.

Financial Impact Assessment

The subsidiary's financial contribution to the parent company was minimal, as detailed in the regulatory disclosure:

Material Impact Statement

IOL Chemicals and Pharmaceuticals Limited has explicitly stated that the strike-off of IOL Life Sciences Limited does not have any material impact on the company's financials or operations. This assessment aligns with the subsidiary's negligible financial contribution to the parent company.

Regulatory Disclosure Requirements

The company has fulfilled all mandatory disclosure requirements under SEBI regulations, providing comprehensive details as required under SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023. The transaction does not fall within related party transactions and is not part of any scheme of arrangement.

The striking off represents a corporate housekeeping measure to streamline the company's subsidiary structure without affecting its core business operations or financial performance.